Loading
MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Skin cancer and 1 more.
Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL.
CIViC holds 3 clinical evidence items and 2 assertions across 1 variant. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.95, animal model 0.45, genetic association 0.52, somatic mutation 0.82).
In plain words · MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Skin cancer and 1 more.
MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Skin cancer and 1 more.
Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves.
No product in this corpus aims at MN1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA MN1: RNA tissue enhanced (blood vessel 22 nTPM, skeletal muscle 47 nTPM); high antibody staining in 27 normal tissues; highest cancer staining skin cancer (8 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Colorectal cancer, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q10571; CIViC gene MN1; Human Protein Atlas MN1 tissue; Open Targets ENSG00000169184 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Deprez R.H.L. et al, Oncogene, 1995, "Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma". Source.
Sources: HGNC HGNC:7180 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q10571 (protein name, function text, keywords and locations (REST API)); CIViC gene MN1 (3 evidence items, 2 assertions, 1 variants; diseases: Astroblastoma, MN1-altered (GraphQL API, CC0)); Open Targets ENSG00000169184 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: colorectal cancer 0.52, melanoma 0.51, skin cancer 0.51, breast cancer 0.60 (GraphQL API, CC0))
Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull. May play a role in tumour suppression. Location: Nucleus (UniProt). Locus 22q12.1 (HGNC).
RNA: tissue enhanced (blood vessel 22 nTPM, skeletal muscle 47 nTPM), detected in many normal tissues.
Medium: Appendix, Duodenum, Fallopian tube, Kidney, Lymph node, Ovary, Stomach.
Medium only: pancreatic cancer, renal cancer, thyroid cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MN1" OR ABSTRACT:"MN1" OR TITLE:"MN1 proto-oncogene, transcriptional regulator" OR ABSTRACT:"MN1 proto-oncogene, transcriptional regulator" OR TITLE:"Transcriptional activator MN1" OR ABSTRACT:"Transcriptional activator MN1" OR TITLE:"MGCR1-PEN" OR ABSTRACT:"MGCR1-PEN" OR TITLE:"MGCR1" OR ABSTRACT:"MGCR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MN1, not a curated reading list.